VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

NIpah Virus G and F Proteins Subunit Vaccine rMV-Ed-G
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0011407
  • Type: Subunit vaccine
  • Status: Research
  • F fusion protein gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • G glycoprotein gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Immunization Route: Subcutaneous injection
  • Vaccine Ontology ID: VO_0004714
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • G glycoprotein gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
    • Detailed Gene Information: Click Here.
  • Preparation: Recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Hamster Response

  • Vaccination Protocol: For protection studies, inbred golden hamsters (Janvier, Le Fenest St. Isles, France) were vaccinated twice (1 month apart) with 107 PFU of vaccinia virus recombinants expressing either the G or F Nipah virus glycoprotein or with 5 × 106 of each of the recombinants when they were used for coimmunization (Guillaume et al., 2004).
  • Challenge Protocol: The animals were challenged 3 months after the last immunization with Nipah virus administered interperitoneally (Guillaume et al., 2004).
  • Efficacy: Hamsters immunized with F and G proteins were completely protected from lethal Nipah virus challenge (Guillaume et al., 2004).

Hamster Response

  • Vaccination Protocol: 8-week-old golden hamsters were intraperitoneally immunized with 2×104 TCID50 of rMV-HL-G or rMV-Ed-G (Yoneda et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: All hamsters were challenged intraperitoneally with 103 TCID50/animal of NiV (Yoneda et al., 2013).
  • Efficacy: All hamsters vaccinated with rMV-HL-G or rMV-Ed-G showed complete protection. During the observation period (14 days after the challenge), all hamsters immunized with the recombinant MVs showed no clinical symptoms of the disease and survived (Yoneda et al., 2013).
References References
Guillaume et al., 2004: Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, Wild TF. Nipah virus: vaccination and passive protection studies in a hamster model. Journal of virology. 2004; 78(2); 834-840. [PubMed: 14694115].
Yoneda et al., 2013: Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PloS one. 2013; 8(3); e58414. [PubMed: 23516477].